Exchange: NASDAQ·Updated 02:12 PM EDT

RPRX News

News
all
press releases
Watch These 2 Energy Stocks — S&P 500 Addition Could Come Before Quarter's End
Bloom Energy and Cheniere Energy are two of the most likely inclusions in the benchmark index, according to Stephens analyst Melissa Roberts.
Stocktwits
More News
MRK, RPRX Stocks Hit 52-Week Highs – What Drove Today’s Gains?
Merck shares rose on growing confidence in its cancer pipeline, while Royalty Pharma hit a record high as Ziihera’s FDA approval strengthened its royalty opportunity.
Stocktwits
If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 27.34% on an annualized basis producing an average annual return of 40.75%. Currently, Royalty Pharma has a market capitalization ofread more...
Benzinga
Here's How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.56%. Currently, Royalty Pharma has a market capitalization ofread more...
Benzinga
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.read more...
Benzinga
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Zacks
Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.94% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Royalty Pharma Q2 Net Income Declines; Raises 2026 Guidance For Portfolio Receipts
(RTTNews) - Royalty Pharma plc (RPRX) reported that its second quarter net income attributable to Royalty Pharma declined to $18 million from $32 million, last year. Adjusted EBITDA increased to $736 million from $633 million. Total income and other revenues was $674 million comp...
Nasdaq News: Markets

Advertisement|Remove ads.